SI-BONE announced that the U.K.'s National Institute for Health and Care Excellence (NICE) published medical technology guidance recommending iFuse® for the treatment of chronic sacroiliac (SI) joint pain. To date, NICE has not recommended another device for to surgically treat the SI joint.
The guidance, titled titled "iFuse for treating chronic sacroiliac joint pain (MTG39)," recommends that:
- The case for adopting iFuse to treat chronic sacroiliac joint pain is supported by the evidence.
- iFuse should be considered for people with a confirmed diagnosis of chronic SI joint pain based on clinical assessment and a positive response to diagnostic injection of local anesthetic in the SI joint.
- The procedure should only be carried out by surgeons who regularly use image-guided surgery for implant placement and have specific training and expertise in minimally invasive SI joint fusion surgery for chronic pain.
In September, SI-BONE was granted exclusive reimbursement by the French National Healthcare System that is effective for five years.